Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.59 |
| ▸ | F10 | P00742 | 4/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832189 | 0.88 | CCR2 (0.71) | CCR2F10GPR35 | |
| Hydrochloric Acid SCHEMBL926656 | 0.87 | CCR2 (0.70) | CCR2F10GPR35 | |
| SCHEMBL926357 | 0.87 | F10 (0.61) | CCR2F10MAPTL3MBTL1IDO1 | |
| SCHEMBL832448 | 0.82 | F10 (0.61) | CCR2F10MAPTL3MBTL1TSHR | |
| SCHEMBL6308068 | 0.81 | CCR2 (0.73) | CCR2PTGS1PTGS2GPR35 | |
| SCHEMBL2006370 | 0.80 | F10 (0.68) | CCR2F10GPR35 | |
| SCHEMBL2900723 | 0.80 | ECE1 (0.58) | CCR2F10 | |
| SCHEMBL939920 | 0.79 | CCR2 (0.59) | CCR2F10GPR35 | |
| SCHEMBL6300900 | 0.79 | CCR2 (0.65) | CCR2F10GPR35 | |
| SCHEMBL940161 | 0.79 | CCR2 (0.59) | CCR2F10GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354425-B2 | Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | disclosed |
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009364-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | ZYX, XDH, ZFX | CCR2 2198/4885F10 1361/4885PTGS1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.